Blog - Page 459 of 5639 - QualityStocks

WednesdayMay 01, 2024 2:26 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Rob Etherington, President, Director and CEO of Clene, was featured in a recent release of From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch. During the interview, Etherington discussed Clene’s work to address the critical unmet medical…

WednesdayMay 01, 2024 2:17 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share; the shares and warrants were originally issued in October 2023 and February 2024, respectively. The company noted that following this exercise, there are no remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. According…

WednesdayMay 01, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024 PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company…

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…

TuesdayApr 30, 2024 12:58 pm

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has entered into agreement with Florida-based Applied Science and Performance Institute (“ASPI”). The agreement outlines plans to conduct a randomized, double-blind, placebo-controlled crossover study designed to assess the safety and efficacy of FSD Pharma’s unbuzzd(TM). The study will be conducted with healthy volunteers in an induced state of alcohol intoxication. A unique dietary supplement with natural ingredients, vitamins and Generally Recognized as Safe (“GRAS”) ingredients, unbuzzd exhibits potential…

TuesdayApr 30, 2024 12:45 pm

QualityStocksNewsBreaks – DealFlow Events Announces Dates, Agenda for Upcoming Annual SPAC Conference

DealFlow Events, host of more than 200 conferences, seminars and webcasts on a variety of financial topics, has released information regarding its upcoming SPAC Conference 2024. The premier event will be on June 11–12, 2024, in New York City. According to the announcement, the seventh annual event is designed to gather a variety of investors, private companies and finance professionals who will delve into the latest trends within the SPAC industry. The event agenda features expert keynote presentations and speakers, including Dan Nash, cofounder of Cohen Capital Markets; Steve Levine, CEO at EarlyBird Capital; Ed Kovary, head of SPAC Capital…

TuesdayApr 30, 2024 11:36 am

QualityStocksNewsBreaks – HealthLynked Corp. (HLYK) Announces Strategic Partnership with IBN

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced that it has joined forces with IBN, a leading financial news and publishing company, to enhance HYLK shareholder communication and spotlight the company’s unique technologies for improving healthcare. The collaboration is set to enhance HealthLynked’s corporate communication efforts and elevate its visibility within the investment community. As part of the client partner relationship, IBN will utilize its extensive investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to IBN will leverage its investor based distribution network of…

TuesdayApr 30, 2024 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Reports 30% YOY Revenue Growth for Q1 2024; Projects $25-$30m Annual Revenue for 2024

Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, just posted 30% year-over-year (“YOY”) revenue growth and a 278% YOY growth in Fr8Fleet volume for Q1 2024 This growth was attributed to the addition of the Fr8Fleet offering in 2022, which sought to address specific customer needs The company looks to build on this success by fostering even stronger relationships with existing customers and adding new customers to its network Its management believes that this approach will be integral in realizing its $25-$30 million annual revenue projection for the 2024 financial year Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a…

TuesdayApr 30, 2024 9:45 am

SUIC Worldwide Holdings Ltd.’s (SUIC) I.Hart Group Expands Franchise Development Efforts with New Authorizations in China and Japan

SUIC recently announced that I.Hart Group Taiwan and MONGA(C) Fried Chicken had signed franchise authorizations in Japan and China The franchise authorizations are expected to grow the number of stores operated by I.Hart Group to 200 outlets in 2024 and more than 500 stores over the next five years The authorizations covering Shandong Province in China will see the Shandong Authorized company opening ten stores during the first year and 300 stores within the subsequent five years. Japan is another authorization which will target the greater Tokyo metropolitan area The new authorizations are part of SUIC’s commitment to grow its…

TuesdayApr 30, 2024 9:00 am

Distributed Energy Solutions Provider Correlate Energy Corp. (CIPI) Uses Quality Toolkit and Financing Incentives to Help Clients Go Affordably Green

Industrial and commercial buildings are responsible for a significant amount of the carbon emissions affecting the planet’s climate, according to pollution experts Correlate Energy Corp. is a distributed energy solutions company, focusing on the North American market, that is dedicated to helping client companies improve their energy use profiles, reducing emissions while maintaining their budgets Correlate is strategically positioned to leverage government financial incentives on its clients’ behalf, as well as offering an array of modern, targeted tools to achieve data-driven solutions The company currently has about $150 million of in-progress projects in various stages of development The drive to…

Site Search

Company Search